326 related articles for article (PubMed ID: 34715852)
21. Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model.
Kim JM; Kim DH; Park HJ; Ma HW; Park IS; Son M; Ro SY; Hong S; Han HK; Lim SJ; Kim SW; Cheon JH
J Nanobiotechnology; 2020 Sep; 18(1):133. PubMed ID: 32933548
[TBL] [Abstract][Full Text] [Related]
22. Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes.
Julsgaard M; Hvas CL; Gearry RB; Gibson PR; Fallingborg J; Sparrow MP; Bibby BM; Connell WR; Brown SJ; Kamm MA; Lawrance IC; Vestergaard T; Svenningsen L; Baekdal M; Kammerlander H; Walsh A; Boysen T; Bampton P; Radford-Smith G; Kjeldsen J; Andrews JM; Subramaniam K; Moore GT; Jensen NM; Connor SJ; Wildt S; Wilson B; Ellard K; Christensen LA; Bell SJ
Inflamm Bowel Dis; 2020 Jan; 26(1):93-102. PubMed ID: 31141607
[TBL] [Abstract][Full Text] [Related]
23. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
Papamichael K; Cheifetz AS; Melmed GY; Irving PM; Vande Casteele N; Kozuch PL; Raffals LE; Baidoo L; Bressler B; Devlin SM; Jones J; Kaplan GG; Sparrow MP; Velayos FS; Ullman T; Siegel CA
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1655-1668.e3. PubMed ID: 30928454
[TBL] [Abstract][Full Text] [Related]
24. Management of the pregnant inflammatory bowel disease patient on anti-tumour necrosis factor: state of the art and future directions.
Leung Y; Panaccione R; Ghosh S; Seow CH
Can J Gastroenterol Hepatol; 2014 Oct; 28(9):505-9. PubMed ID: 25101334
[TBL] [Abstract][Full Text] [Related]
25. Oral delivery of anti-TNF antibody shielded by natural polyphenol-mediated supramolecular assembly for inflammatory bowel disease therapy.
Wang X; Yan J; Wang L; Pan D; Xu Y; Wang F; Sheng J; Li X; Yang M
Theranostics; 2020; 10(23):10808-10822. PubMed ID: 32929381
[No Abstract] [Full Text] [Related]
26. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy in inflammatory bowel disease: Novel and emerging treatments.
Catalan-Serra I; Brenna Ø
Hum Vaccin Immunother; 2018; 14(11):2597-2611. PubMed ID: 29624476
[TBL] [Abstract][Full Text] [Related]
28. Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.
Toussirot É; Houvenagel É; Goëb V; Fouache D; Martin A; Le Dantec P; Dernis E; Wendling D; Ansemant T; Berthelot JM; Bader-Meunier B; Kantelip B;
Joint Bone Spine; 2012 Oct; 79(5):457-63. PubMed ID: 22088934
[TBL] [Abstract][Full Text] [Related]
29. Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review.
Wang LF; Chen PR; He SK; Duan SH; Zhang Y
World J Gastroenterol; 2023 Aug; 29(29):4481-4498. PubMed ID: 37621757
[TBL] [Abstract][Full Text] [Related]
30. TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User's Guide: An Update.
Vulliemoz M; Brand S; Juillerat P; Mottet C; Ben-Horin S; Michetti P;
Digestion; 2020; 101 Suppl 1():16-26. PubMed ID: 32739923
[TBL] [Abstract][Full Text] [Related]
31. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F
United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
[TBL] [Abstract][Full Text] [Related]
32. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease.
Hoentjen F; van Bodegraven AA
World J Gastroenterol; 2009 May; 15(17):2067-73. PubMed ID: 19418577
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers.
Cui G; Fan Q; Li Z; Goll R; Florholmen J
EBioMedicine; 2021 Apr; 66():103329. PubMed ID: 33862588
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity of High Dose Influenza Vaccine for Patients with Inflammatory Bowel Disease on Anti-TNF Monotherapy: A Randomized Clinical Trial.
Caldera F; Hillman L; Saha S; Wald A; Grimes I; Zhang Y; Sharpe AR; Reichelderfer M; Hayney MS
Inflamm Bowel Dis; 2020 Mar; 26(4):593-602. PubMed ID: 31504526
[TBL] [Abstract][Full Text] [Related]
35. Increased Discontinuation Rates of Anti-TNF Therapy in Elderly Inflammatory Bowel Disease Patients.
de Jong ME; Smits LJT; van Ruijven B; den Broeder N; Russel MGVM; Römkens TEH; West RL; Jansen JM; Hoentjen F
J Crohns Colitis; 2020 Jul; 14(7):888-895. PubMed ID: 31974546
[TBL] [Abstract][Full Text] [Related]
36. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages.
Atreya R; Zimmer M; Bartsch B; Waldner MJ; Atreya I; Neumann H; Hildner K; Hoffman A; Kiesslich R; Rink AD; Rau TT; Rose-John S; Kessler H; Schmidt J; Neurath MF
Gastroenterology; 2011 Dec; 141(6):2026-38. PubMed ID: 21875498
[TBL] [Abstract][Full Text] [Related]
37. Oral Lichen Planus in IBD Patients: A Paradoxical Adverse Effect of Anti-TNF-α Therapy.
Andrade P; Lopes S; Albuquerque A; Osório F; Pardal J; Macedo G
Dig Dis Sci; 2015 Sep; 60(9):2746-9. PubMed ID: 25917051
[TBL] [Abstract][Full Text] [Related]
38. Could Mucosal TNF Transcript as a Biomarker Candidate Help Optimize Anti-TNF Biological Therapy in Patients With Ulcerative Colitis?
Cui G; Florholmen J; Goll R
Front Immunol; 2022; 13():881112. PubMed ID: 35663996
[TBL] [Abstract][Full Text] [Related]
39. Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management.
Terrin M; Migliorisi G; Dal Buono A; Gabbiadini R; Mastrorocco E; Quadarella A; Repici A; Santoro A; Armuzzi A
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511260
[TBL] [Abstract][Full Text] [Related]
40. Can We Predict the Efficacy of Anti-TNF-α Agents?
Lopetuso LR; Gerardi V; Papa V; Scaldaferri F; Rapaccini GL; Gasbarrini A; Papa A
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28906475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
